3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
202
Recurrence
53
Neoplasms, Plasma Cell
19
Neoplasms
12
Immunoglobulin Light-chain Amyloidosis
10
Hematologic Diseases
4
Amyloidosis
4
Renal Insufficiency
3
Lymphoma, Non-Hodgkin
3
Blood Protein Disorders
3
Plasmacytoma
2
Paraproteinemias
2
Neoplasms by Histologic Type
2
Disease Progression
2
Chromosome 17 deletion
2
Waldenstrom Macroglobulinemia
1
Smoldering Multiple Myeloma
1
Proteostasis Deficiencies
1
Malignant Plasma Cell Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Acute
1
Hypoxia
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Disease
1
Corneal Diseases
1
Alzheimer Disease
1
Interventions
fludarabine phosphate
4
Dexamethasone
4
Peripheral Blood Stem Cell Transplantation
3
Melphalan
3
pomalidomide
2
Whole-Body Irradiation
2
Tacrolimus
2
Mycophenolic Acid
2
ixazomib
1
fludarabine
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
daratumumab
1
carmustine, poliferprosan 20 drug combination
1
auricularum
1
Sirolimus
1
RG7388
1
Maintenance
1
Etoposide
1
Cytarabine
1
Cyclosporins
1
Cyclosporine
1
Cyclophosphamide
1
Carmustine
1
Calcium Dobesilate
1
Bortezomib
1
Atorvastatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Chromosome 17 deletion
×
pomalidomide
×
Plasma cell
×
Clear all
NCT01745640
2026-02-05
IFM2010-02
University Hospital, Lille
Phase 2
Completed
63 enrolled
NCT04124497
2025-08-08
DPd
Fondazione EMN Italy Onlus
Phase 2
Active not recruiting
45 enrolled